{"id":700433,"date":"2024-05-24T11:32:01","date_gmt":"2024-05-24T11:32:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=700433"},"modified":"2024-05-24T11:32:01","modified_gmt":"2024-05-24T11:32:01","slug":"cuttingedge-medical-innovations-propel-catheter-precision-inc-nyse-american-vtak-forward","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/cuttingedge-medical-innovations-propel-catheter-precision-inc-nyse-american-vtak-forward_700433.html","title":{"rendered":"\u201cCutting-Edge Medical Innovations Propel Catheter Precision Inc. (NYSE American: VTAK) Forward\u201d"},"content":{"rendered":"
\"“Cutting-Edge<\/a><\/div>\n

The medical device sector in the healthcare industry has rapidly advanced in recent years due to its inherent innovation, and Catheter Precision Inc. (NYSE American: VTAK)<\/strong> stands out as a notable player in the healthcare electrophysiology sector. The company is renowned for its two key products: VIVO™<\/strong><\/a>, aiding in ventricular arrhythmia source detection pre-procedure, and LockeT<\/a><\/strong>, a closure retention device. Read Entire Summary Update Now!<\/a><\/p>\n

 <\/p>\n

\"\"<\/strong><\/p>\n

Catheter Precision Inc. (NYSE American: VTAK)<\/strong> announced that Ronald Reagan UCLA Medical Center<\/strong> and Rady Children’s Hospital<\/strong> in San Diego, the University of California San Diego (UCSD)<\/strong> health system and HCA Healthcare<\/strong> Inc. (NYSE: HCA)<\/strong> all making initial purchases of their LockeT <\/strong>product. HCA Healthcare Inc.,<\/strong> a leading provider of healthcare services in the United States, generating over $64 billion in revenue in 2023. It operates 186 hospitals and approximately 2,400 care sites across 20 states and throughout the United Kingdom. The potential inclusion of additional prestigious academic institutions in the near to mid-term should not be unexpected. Insider Financial Special Feature Read Now!<\/a>  <\/strong> <\/p>\n

In Q1, the company expanded its sales team by adding several industry veterans. The expanded team aims to grow the marketing footprint into new markets and further penetrate existing ones. The company released the first-ever data on the preliminary clinical study of LockeT. In a study with 100 patients, there was 100% immediate hemostasis and same-day discharge. The study also showed LockeT’s effectiveness for wound closure up to 27F, reducing the need for multiple closure devices. <\/p>\n

Active across these sectors, healthcare industry companies include: Mangoceuticals Inc (NASDAQ: MGRX), Biodexa Pharmaceuticals PLC-ADR (NASDAQ: BDRX), Citius Pharmaceuticals Inc (NASDAQ: CTXR), Novavax Inc (NASDAQ: NVAX), Ocugen Inc (NASDAQ: OCGN).<\/p>\n

 <\/p>\n

Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content.”TSR” is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. “TSR” authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. “TSR” has not been compensated to produce content related to “Any Companies” appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.<\/p>\n

Media Contact<\/span>
Company Name:<\/strong> The Street Reports<\/a>
Contact Person:<\/strong> Editor
Email:<\/strong> Send Email<\/a>
Country:<\/strong> United States
Website:<\/strong> http:\/\/www.thestreetreports.com <\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

The medical device sector in the healthcare industry has rapidly advanced in recent years due to its inherent innovation, and Catheter Precision Inc. (NYSE American: VTAK) stands out as a notable player in the healthcare electrophysiology sector. The company is renowned for … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[426,405,412,406,411],"tags":[],"class_list":["post-700433","post","type-post","status-publish","format-standard","hentry","category-Financial-Market","category-Health-Medicine","category-News-Current-Affairs","category-Pharmaceuticals-Biotech","category-Technology"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/700433","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=700433"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/700433\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=700433"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=700433"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=700433"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}